Bessemer Group’s Dyne Therapeutics DYN Stock Holding History

Bessemer Group’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-60	Closed	-$2K	–	2507
2024 Q3	$2K	Buy	+60	New	+$2.39K	﹤0.01%	2189

Other funds holding DYN

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bessemer Group's DYN Position: Q4 2024 in Review

Bessemer Group sold out of Dyne Therapeutics (DYN) in Q4 2024, closing a stake of 60 shares — an estimated $2K sold.

Bessemer Group first reported a position in DYN in Q3 2024 and held it in 1 quarter. The position peaked at $2K in Q3 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q4 2024.

Bessemer Group reported no remaining Dyne Therapeutics position as of Q4 2024 after selling out during the quarter.
Bessemer Group sold 60 Dyne Therapeutics shares in Q4 2024, an estimated $2K.
Bessemer Group first reported a position in Dyne Therapeutics in Q3 2024 and held it in 1 quarter.
Bessemer Group's Dyne Therapeutics position peaked at $2K in Q3 2024.
200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.